Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used?
A 5-year nationwide prospective study in Sweden during 1995-1999 identified 881 definite episodes of infective endocarditis. Definite enterococcal endocarditis was diagnosed in 93 episodes (11%), the largest series of enterococcal endocarditis so far presented. Mortality during treatment was 16%, the relapse rate was 3%, and clinical cure was achieved in the remaining 81% of the episodes. Clinical cure was achieved with a median duration of cell wall-active antimicrobial therapy of 42 days combined with an aminoglycoside (median treatment time, 15 days). International guidelines generally recommend a 4-6-week combined synergistic treatment course with a cell wall-active antibiotic and an aminoglycoside. Treatment regimens in Sweden often include a shortened aminoglycoside treatment course in order to minimize adverse effects in older patients. Fatal outcome seemed not to be due to the shortened aminoglycoside therapy course. In many enterococcal endocarditis episodes, duration of aminoglycoside therapy could probably be shortened to 2-3 weeks.
Olaison
Lars
L
Department of Infectious Diseases, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden. lars.olaison@medfak.gu.se
Schadewitz
Kimmo
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D013293:Enterococcus faecalis / Q000187:drug effects / Q000302:isolation & purification; D016984:Enterococcus faecium / Q000187:drug effects / Q000302:isolation & purification; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D006350:Heart Valve Prosthesis / Q000382:microbiology; D006801:Humans; D007769:Lactams; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D055502:Secondary Prevention; D013290:Streptococcal Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D013291:Streptococcus / Q000187:drug effects / Q000302:isolation & purification; D013548:Sweden / Q000453:epidemiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D007769:Lactams